A comparison of Scemblix (asciminib) and Bosulif (bosutinib) demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase ...
Credit: Getty Images. A new capsule dosage form has also been approved in 50mg and 100mg strengths. The Food and Drug Administration (FDA) has approved Bosulif ...
It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
Asciminib, a first-in-class BCR-ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line ...
This publication is sponsored by Takeda Pharmaceuticals U.S.A., Inc. This clinical brief provides key information on third-generation tyrosine kinase inhibitor for patients with chronic phase chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback